AGENUS INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Cancer

Interventions: Drug: AGEN2373
Drug: Botensilimab

First Posted Date: 2019-10-10

Last Posted Date: 2024-04-01

Lead Sponsor: Agenus Inc.

Target Recruit Count: 67

Registration Number: NCT04121676

Locations: 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸
Roswell Park Comprehensive Cancer Care, Buffalo, New York, United States
🇺🇸
Columbia University, New York, New York, United States

and more 9 locations

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Phase 2

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Drug: AGEN2034
Drug: AGEN1884

First Posted Date: 2019-03-28

Last Posted Date: 2024-12-12

Lead Sponsor: Agenus Inc.

Target Recruit Count: 212

Registration Number: NCT03894215

Locations: 🇺🇸
UCLA- Women's Health Clinical Research Unit (WHCRU), Los Angeles, California, United States
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Columbus NCORP, Columbus, Ohio, United States

and more 65 locations

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Phase 1

Recruiting

Conditions: Advanced Cancer
Non-small-cell Lung Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer Without Liver Metastases
Endometrial Cancer
Fibrolamellar Carcinoma
Angiosarcoma

Interventions: Drug: Botensilimab
Drug: Balstilimab

First Posted Date: 2019-03-01

Last Posted Date: 2024-08-28

Lead Sponsor: Agenus Inc.

Target Recruit Count: 550

Registration Number: NCT03860272

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Providence Portland Cancer Center, Portland, Oregon, United States

and more 16 locations

Phase 1a Study to Evaluate Immunogenicity of ASV®

Phase 1

Completed

Conditions: Solid Tumor, Adult

Interventions: Biological: ASV® AGEN2017 + QS-21 Stimulon® adjuvant

First Posted Date: 2018-09-17

Last Posted Date: 2021-12-02

Lead Sponsor: Agenus Inc.

Target Recruit Count: 3

Registration Number: NCT03673020

Locations: 🇺🇸
School of Medicine at the University of Miami, Miami, Florida, United States

Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Phase 1

Completed

Conditions: Cervical Cancer

Interventions: Drug: AGEN1884 + AGEN2034

First Posted Date: 2018-04-12

Last Posted Date: 2023-07-05

Lead Sponsor: Agenus Inc.

Target Recruit Count: 154

Registration Number: NCT03495882

Locations: 🇺🇸
Chattanooga's Program In Women's Oncology, Chattanooga, Tennessee, United States
🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

and more 44 locations

Study of AGEN1884 With Pembrolizumab in 1L NSCLC

Phase 2

Terminated

Conditions: NSCLC Stage IV

Interventions: Biological: AGEN1884 in combination with pembrolizumab

First Posted Date: 2018-01-26

Last Posted Date: 2020-06-02

Lead Sponsor: Agenus Inc.

Target Recruit Count: 2

Registration Number: NCT03411473

Locations: 🇦🇺
Mater Research, Brisbane, Australia
🇦🇺
Sydney Adventist, Wahroonga, Australia
🇦🇺
Scientia Clinical Research, Sydney, Australia

and more 2 locations

Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Phase 1

Completed

Conditions: Cervical Cancer
Advanced Cancer

Interventions: Drug: AGEN2034

First Posted Date: 2017-04-07

Last Posted Date: 2023-06-05

Lead Sponsor: Agenus Inc.

Target Recruit Count: 211

Registration Number: NCT03104699

Locations: 🇺🇸
University of Southern California - Keck School of Medicine, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸
Augusta Oncology, Augusta, Georgia, United States

and more 41 locations

Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Biological: AutoSynVax™ vaccine

First Posted Date: 2016-12-14

Last Posted Date: 2020-06-02

Lead Sponsor: Agenus Inc.

Target Recruit Count: 3

Registration Number: NCT02992977

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
School of Medicine at the University of Miami, Miami, Florida, United States

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Phase 1

Completed

Conditions: Advanced Solid Cancers
Advanced Solid Cancers Refractory to PD-1

Interventions: Drug: AGEN1884

First Posted Date: 2016-03-01

Last Posted Date: 2023-02-27

Lead Sponsor: Agenus Inc.

Target Recruit Count: 88

Registration Number: NCT02694822

Locations: 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States

and more 8 locations

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Phase 2

Completed

Conditions: Herpes Simplex Type 2

Interventions: Drug: HerpV and QS-21
Drug: Placebo

First Posted Date: 2012-09-19

Last Posted Date: 2021-07-13

Lead Sponsor: Agenus Inc.

Target Recruit Count: 80

Registration Number: NCT01687595

Locations: 🇺🇸
Center for Clinical Studies - Cypress, Houston, Texas, United States
🇺🇸
Westover Heights Clinic, Portland, Oregon, United States
🇺🇸
Center for Clinical Studies - Texas Medical Center, Houston, Texas, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy